Skip to content
Newsroom
Certifications
About Us
Contact Us
Become One
Student
Individual
Fellow
Newsroom
Certifications
About Us
Contact Us
Become One
Student
Individual
Fellow
Login
Clostridium difficile
Clostridium difficile
Latest Posts
Cidrap EDU
,
Clostridium difficile
,
RSS
Treating recurrent C difficile cases cost hospital millions, study finds
October 2, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
Survey finds low but rising public awareness of C diff
September 27, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
Study highlights optimal strategies for fecal transplantation in C diff patients
June 25, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
Trial data show Rebyota is safe, effective in immune-compromised patients with recurrent C diff
April 4, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
Study examines C diff recurrence, risk factors in cancer patients
April 4, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
Study highlights demographic, socioeconomic disparities in C difficile infection
April 4, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
Fidaxomicin underused for C diff infections, study finds
April 4, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
VA trial finds no reduction in C diff recurrence after fecal microbiota therapy
April 4, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
Narrow-spectrum drug shows promise against C diff infection in phase 2 trial
April 4, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
C difficile vaccine candidate fails to meet primary end point in phase 3 trial
April 4, 2025
Load More
× Clear
Categories
Rss
Cidrap Edu
Cna Asia
Ecdc Europa
New York Times News
Times of India
Sub-categories
Cidrap EDU
,
Clostridium difficile
,
RSS
Treating recurrent C difficile cases cost hospital millions, study finds
October 2, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
Survey finds low but rising public awareness of C diff
September 27, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
Study highlights optimal strategies for fecal transplantation in C diff patients
June 25, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
Trial data show Rebyota is safe, effective in immune-compromised patients with recurrent C diff
April 4, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
Study examines C diff recurrence, risk factors in cancer patients
April 4, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
Study highlights demographic, socioeconomic disparities in C difficile infection
April 4, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
Fidaxomicin underused for C diff infections, study finds
April 4, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
VA trial finds no reduction in C diff recurrence after fecal microbiota therapy
April 4, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
Narrow-spectrum drug shows promise against C diff infection in phase 2 trial
April 4, 2025
Cidrap EDU
,
Clostridium difficile
,
RSS
C difficile vaccine candidate fails to meet primary end point in phase 3 trial
April 4, 2025
×
Download
Share to LinkedIn
